Depo-Provera Lawsuit Settlement Update 2026: Town Hall Meeting, MSA Details & Payout Timeline

Last Updated: August 8, 2026 | Reviewed by: TortAdvisor Editorial Team | Primary Sources: U.S. District Court, N.D. Florida (MDL 3140); AboutLawsuits.com; FDA

Latest Depo-Provera Lawsuit Settlement News

The Depo-Provera lawsuit settlement moved a significant step forward on July 27, 2026, when U.S. District Judge M. Casey Rodgers held a case management conference in the federal multidistrict litigation (MDL 3140) centralized in the Northern District of Florida. Attorneys confirmed they had finished negotiating a Master Settlement Agreement (MSA) intended to resolve the bulk of the nearly 6,300 pending federal claims brought by women who allege the birth control injection caused them to develop meningioma brain tumors.

Despite the milestone, the specific terms of the Depo-Provera lawsuit settlement have not been made public. According to the court’s case management order, the agreement includes a confidentiality provision that prevents eligibility criteria and payout structures from being disclosed outside of a planned town hall meeting for plaintiffs and their attorneys. As of early August 2026, no firm date for that meeting had been scheduled.

The conference also brought together judges overseeing related state court litigation, including New York Justice Sabrina Kraus and Delaware Judge Kathleen Vavala, reflecting how closely the federal and state tracks are being coordinated as the settlement moves toward implementation.

Inside the Master Settlement Agreement

While the full text of the Depo-Provera lawsuit settlement remains confidential, the case management order gives some insight into how the process will unfold. Judge Rodgers indicated that any plaintiff who is determined to be eligible under the MSA will keep that eligibility regardless of how the court rules on other pending motions, including a summary judgment motion filed by Pfizer arguing that plaintiffs cannot prove their injections caused a brain tumor.

In other words, even if Pfizer wins on some legal arguments later in the litigation, women already deemed eligible under the settlement terms are expected to remain part of the compensation program. Mass tort settlements of this size typically rely on a points-based grid that weighs factors such as duration of Depo-Provera use, tumor size and location, whether surgery was required, and ongoing medical monitoring needs — though TortAdvisor has not independently confirmed that this specific structure applies here, since those details are still confidential.

The settlement is also notable for how it intersects with parallel state court litigation. Coordination between the federal MDL and courts in New York, Delaware, California, Minnesota and Connecticut suggests the final resolution could extend well beyond the federal docket alone.

Depo-Provera Settlement Timeline

The figure below traces how the Depo-Provera lawsuit settlement has progressed from the first bellwether preparations through the finalized Master Settlement Agreement.

Where Cases Stand, Court by Court

A joint status report filed July 27, 2026 gives the clearest public picture yet of how Depo-Provera meningioma claims are distributed across federal and state courts.

Why Women Are Filing Depo-Provera Lawsuits

Depo-Provera (medroxyprogesterone acetate) is a long-acting birth control injection that has been on the U.S. market since the 1990s and used by tens of millions of women, providing roughly three months of contraceptive protection per shot. The current wave of litigation traces back to a 2024 study that found women who used Depo-Provera for an extended period faced a meningioma risk roughly five times higher than non-users.

Meningiomas form in the membranes surrounding the brain and spinal cord. While usually non-cancerous, they can grow large enough to press on brain tissue and nerves, often requiring complex surgery, radiation, or lifelong monitoring. Plaintiffs allege Pfizer and Pharmacia knew or should have known about this risk long before it was disclosed to U.S. patients.

That allegation is bolstered by regulatory history: Canadian and European drug labels have carried meningioma warnings for roughly a decade, while the U.S. label lacked equivalent language until the FDA approved an updated warning in late 2025. Critics of the manufacturer argue this gap left millions of American women uninformed about a risk that regulators abroad had already flagged.

Figure 3: Key statistics behind the Depo-Provera meningioma litigation. Sources: AboutLawsuits.com (July 13 & July 30, 2026); FDA labeling update.

Am I Eligible for the Depo-Provera Settlement?

Because the eligibility criteria in the Master Settlement Agreement remain confidential until the town hall meeting, no one can say with certainty who will qualify. Based on the underlying lawsuits and court filings, however, women generally being considered in this litigation share a few common characteristics: they received repeated Depo-Provera (or generic medroxyprogesterone acetate) injections, often over a period of a year or more, and were later diagnosed with a meningioma or similar brain tumor that required surgery, radiation, or ongoing imaging and monitoring.

If you received Depo-Provera injections and were later diagnosed with a brain tumor, the safest step is to speak with an attorney who can review your medical and prescription records against whatever eligibility criteria are ultimately released. Missing a claim deadline or registration window could affect your ability to participate in the settlement.

Pilot Trials Still Moving Forward

Even as the settlement advances, Judge Rodgers has kept the litigation’s bellwether trial process alive for claims that fall outside the settlement’s scope. Earlier “pilot” cases were dropped from the trial track once it became clear those particular plaintiffs qualified for the settlement. Counsel and the court have since selected three new pilot plaintiffs — Christina Yeager, Vivian Davis, and Katherine Allison Ponder — whose cases involve circumstances that make them ineligible for the current settlement terms.

These trials matter because they help both sides gauge how a jury might view evidence and testimony that could be repeated across thousands of remaining claims if the broader settlement does not resolve every case. If some claims cannot be resolved through the settlement or subsequent bellwether verdicts, Judge Rodgers may send those cases back to the federal districts where they originated for individual trial dates.

What Happens Next

Attorneys have indicated that settlement registration should be completed by November 2026, with the claims process and first payments expected to begin during the first quarter of 2027, according to the court’s July 27 case management order. Before that happens, plaintiffs are still waiting on a scheduled town hall meeting where the confidential details of the Depo-Provera lawsuit settlement — including eligibility rules and how compensation will be calculated — will finally be shared.

The next case management conference in the MDL is set for September 18, 2026, when the court expects an updated joint report from attorneys representing the federal and state court tracks. Anyone with a pending or potential Depo-Provera claim should stay in close contact with their attorney in the coming months, since registration windows in mass tort settlements are often strict and non-negotiable.

For general background on the underlying litigation, including MDL structure and filing deadlines, see TortAdvisor’s Depo-Provera Lawsuit overview.

Frequently Asked Questions

How much money will the Depo-Provera lawsuit settlement pay out?
Specific payout amounts have not been released. The Master Settlement Agreement is confidential until eligibility details are shared at the upcoming town hall meeting.

When will the Depo-Provera lawsuit settlement be paid?
Attorneys indicated registration should be completed in November 2026, with claims processing and the first payments beginning in the first quarter of 2027.

How do I know if I qualify for the Depo-Provera settlement?
Eligibility criteria remain confidential. Women who received repeated Depo-Provera injections and were later diagnosed with a meningioma are encouraged to speak with an attorney to review their records once details are released.

What happens if my case doesn’t qualify for the settlement?
Cases that fall outside the settlement terms may proceed toward bellwether trials or be remanded to their originating federal district for an individual trial date.

Is Depo-Provera still available, and does it carry a brain tumor warning?
Yes, Depo-Provera remains available in the U.S. The FDA approved an updated label in late 2025 warning about meningioma risk, following similar warnings already required in Canada and Europe.

This article is for informational purposes only and does not constitute legal advice. Settlement terms, deadlines and eligibility criteria described above are based on publicly available court filings and news reporting as of the last-updated date and are subject to change.